MX2020005099A - Metodo de produccion de un compuesto intermedio para sintetizar un medicamento. - Google Patents

Metodo de produccion de un compuesto intermedio para sintetizar un medicamento.

Info

Publication number
MX2020005099A
MX2020005099A MX2020005099A MX2020005099A MX2020005099A MX 2020005099 A MX2020005099 A MX 2020005099A MX 2020005099 A MX2020005099 A MX 2020005099A MX 2020005099 A MX2020005099 A MX 2020005099A MX 2020005099 A MX2020005099 A MX 2020005099A
Authority
MX
Mexico
Prior art keywords
intermediate compound
preparing intermediate
synthesizing
synthesizing pharmaceutical
sub
Prior art date
Application number
MX2020005099A
Other languages
English (en)
Inventor
Seok Ju Lee
Bongchan Kim
In Ae Ryu
Jongwon Park
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Priority claimed from KR1020180126663A external-priority patent/KR102184129B1/ko
Publication of MX2020005099A publication Critical patent/MX2020005099A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método de preparación de fórmula química 1 que es un producto intermedio necesario para sintetizar antidiabéticos que inhiben la DPP-IV desprotegiendo selectivamente el grupo protector de ácido carboxílico (P2) del compuesto de fórmula química 2.
MX2020005099A 2017-11-16 2018-10-23 Metodo de produccion de un compuesto intermedio para sintetizar un medicamento. MX2020005099A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170153334 2017-11-16
KR1020180126663A KR102184129B1 (ko) 2017-11-16 2018-10-23 의약품 합성용 중간체 화합물의 제조 방법
PCT/KR2018/012575 WO2019098551A1 (ko) 2017-11-16 2018-10-23 의약품 합성용 중간체 화합물의 제조 방법

Publications (1)

Publication Number Publication Date
MX2020005099A true MX2020005099A (es) 2020-08-13

Family

ID=66538632

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005099A MX2020005099A (es) 2017-11-16 2018-10-23 Metodo de produccion de un compuesto intermedio para sintetizar un medicamento.

Country Status (2)

Country Link
MX (1) MX2020005099A (es)
WO (1) WO2019098551A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2721185A1 (de) * 1977-05-11 1978-11-16 Bayer Ag Verfahren zur herstellung von substituierten vinylcyclopropancarbonsaeurebenzylestern
JPH04316526A (ja) * 1991-04-15 1992-11-06 Asahi Chem Ind Co Ltd カルボン酸エステルのアルカリ加水分解法
TW460452B (en) * 1998-09-14 2001-10-21 Rhodia Fiber & Amp Resin Inter Process for the crystallization of carboxylic acid and process for manufacturing crystalline carboxylic acid
JP2008201719A (ja) * 2007-02-20 2008-09-04 Nippon Oil Corp テトラカルボン酸およびその酸二無水物の製造方法
JP5705985B2 (ja) * 2010-09-03 2015-04-22 エルジー・ライフ・サイエンシーズ・リミテッドＬＧ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 医薬品合成用中間体化合物の製造方法

Also Published As

Publication number Publication date
WO2019098551A1 (ko) 2019-05-23

Similar Documents

Publication Publication Date Title
MX2021003460A (es) Fabricacion de compuestos y composiciones para inhibir la actividad de shp2.
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
MX2021003459A (es) Proceso de fabricacion de un compuesto para la inhibicion de la actividad de shp2.
AU2015293541B2 (en) Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
IN2014MN02106A (es)
PH12015501226A1 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
MX2013011257A (es) Proceso para la preparacion de dronedarona por n-butilacion.
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
IN2014MN01521A (es)
MX366820B (es) Moduladores de gpr120 del acido biciclo[2.2.2].
SG11201906688VA (en) Novel ester compounds, method for the production thereof and use thereof
EA201892515A1 (ru) Стероидные 6,7-бета-эпоксиды в качестве интермедиатов
WO2016038628A3 (en) A process for preparing olodaterol and intermediates thereof
UA103329C2 (ru) Соли соединений-ингибиторов вич
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
IN2015DN02424A (es)
MX2020012691A (es) Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico.
MX2011009898A (es) Proceso para la obtencion de derivados de acido propionico.
SA516371323B1 (ar) مركبات بيرازول فلورو فينيل
MX2020005099A (es) Metodo de produccion de un compuesto intermedio para sintetizar un medicamento.
PH12020550635A1 (en) Production method of intermediate compound for synthesizing medicament
CA2928305C (en) A crystalline anhydrous form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof